Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy

Launched by AARHUS UNIVERSITY HOSPITAL · Oct 1, 2024

Keywords

ClinConnect Summary

This clinical trial is looking to understand how starting antihormone therapy affects the metabolic health of patients with early breast cancer. Specifically, the researchers want to see if there are early changes in things like weight, blood pressure, and blood sugar levels after patients begin treatment. They believe that within the first three months of starting this therapy, there may be a decline in metabolic health, even as hormone levels decrease. The study will include about 112 patients at Aarhus University Hospital over six months, starting in the autumn of 2024.

To participate, you need to be at least 18 years old, have a specific type of breast cancer (called estrogen receptor-positive or ER+), and not be receiving treatment for diabetes. If you join, you will have two check-ups: one on the day you start your therapy and another three months later, during which your height, weight, waist and hip sizes, and blood samples will be taken to monitor any changes. It’s important to note that if you are pregnant, breastfeeding, or have certain personal circumstances that might make it difficult to follow the study, you will not be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Invasive ER+ breast cancer
• • No diabetes treatment
• • Planned for initiation of any adjuvant endocrine therapy.
• Exclusion Criteria:
• • Pregnancy or lactation,
• • Psychological, familial, sociological, or geographical conditions potentially hampering compliance with the study protocol and follow-up schedule; these conditions will be discussed with the patient before registration in the trial.